Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 742

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing

Open access
Kimmel, Stephen E., French, Benjamin, Kasner, Scott E., Johnson, Julie A., Anderson, Jeffrey L., Gage, Brian F., Rosenberg, Yves D., Eby, Charles S., Madigan, Rosemary A., McBane, Robert B., Abdel-Rahman, Sherif Z., Stevens, Scott M., Yale, Steven, Mohler, Emile R., Fang, Margaret C., Shah, Vinay, Horenstein, Richard B., Limdi, Nita A., Muldowney, James A.S., Gujral, Jaspal, Delafontaine, Patrice, Desnick, Robert J., Ortel, Thomas L., Billett, Henny H., Pendleton, Robert C., Geller, Nancy L., Halperin, Jonathan L., Goldhaber, Samuel Z., Caldwell, Michael D., Califf, Robert M., Ellenberg, Jonas H. · 2013 · New England Journal of Medicine

Abstract

BACKGROUND: The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results. METHODS: We randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a dosing algorithm that included both clinical variables and genotype data or to one that included clinical variables only. All patients and clinicians were unaware of the dose of warfarin during the first 4 weeks of therapy. The primary outcome was the percentage of time that the international normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of therapy. RESULTS: At 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group and 45.4% in the clinically guided group (adjusted mean difference, [genotype-guided group minus clinically guided group], -0.2; 95% confidence interval, -3.4 to 3.1; P=0.91). There also was no significant between-group difference among patients with a predicted dose difference between the two algorithms of 1 mg per day or more. There was, however, a significant interaction between dosing strategy and race (P=0.003). Among black patients, the mean percentage of time in the therapeutic range was less in the genotype-guided group than in the clinically guided group. The rates of the combined outcome of any INR of 4 or more, major bleeding, or thromboembolism did not differ significantly according to dosing strategy. CONCLUSIONS: Genotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy. (Funded by the National Heart, Lung, and Blood Institute and others; COAG ClinicalTrials.gov number, NCT00839657.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1310669

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

Metadata

Authors
Kimmel, S. E., French, B., Kasner, S. E., Johnson, J. A., Anderson, J. L., Gage, B. F., Rosenberg, Y. D., Eby, C. S., Madigan, R. A., McBane, R. B., Abdel-Rahman, S. Z., Stevens, S. M., Yale, S., Mohler, E. R., Fang, M. C., Shah, V., Horenstein, R. B., Limdi, N. A., Muldowney, J. A. S., Gujral, J., Delafontaine, P., Desnick, R. J., Ortel, T. L., Billett, H. H., Pendleton, R. C., Geller, N. L., Halperin, J. L., Goldhaber, S. Z., Caldwell, M. D., Califf, R. M., & Ellenberg, J. H.
Venue
New England Journal of Medicine
Published
2013-12-12
Volume
369
Issue
24
Pages
2283-2293
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2128189669
Cited by
742
References
22
FWCI
111.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.